Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B7 | P16662 | 7/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
| ▸ | GRM6 | O15303 | 2/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.30 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3988738 | 0.83 | EPHX1 (0.42) | UGT2B7EPHX1 | |
| SCHEMBL3988679 | 0.76 | ALDH1A1 (0.40) | UGT2B7 | |
| SCHEMBL4607753 | 0.76 | UGT2B7 (0.45) | UGT2B7CYP1A2EPHX1APLNRSLC1A2 | |
| SCHEMBL7169835 | 0.76 | UGT2B7 (0.45) | UGT2B7CYP1A2EPHX1APLNRSLC1A2 | |
| SCHEMBL4147353 | 0.76 | UGT2B7 (0.45) | UGT2B7CYP1A2EPHX1APLNRSLC1A2 | |
| SCHEMBL4152571 | 0.76 | UGT2B7 (0.45) | UGT2B7CYP1A2EPHX1APLNRSLC1A2 | |
| SCHEMBL4152574 | 0.76 | UGT2B7 (0.45) | UGT2B7CYP1A2EPHX1APLNRSLC1A2 | |
| SCHEMBL4607755 | 0.76 | UGT2B7 (0.45) | UGT2B7CYP1A2EPHX1APLNRSLC1A2 | |
| SCHEMBL9821111 | 0.74 | UGT2B7 (0.44) | UGT2B7CYP1A2EPHX1APLNRSLC1A2 | |
| SCHEMBL3987464 | 0.74 | UGT2B7 (0.54) | UGT2B7CYP1A2APLNRSLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562575-B1 | FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY | ABBOTT LAB (US) | 2009-05-20 | — | — | EP | claimed |
| US-20040209859-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-10-21 | — | — | US | claimed |
| US-20040077617-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-04-22 | — | — | US | claimed |
| EP-1562575-B1 | FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY | ABBOTT LAB (US) | 2009-05-20 | — | — | EP | disclosed |
| US-20040209859-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-10-21 | — | — | US | disclosed |
| US-20040077617-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209859-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | GRIN2A, GRIK1, GRIN2B | UGT2B7 1481/4885CYP1A2 907/4885EPHX1 1196/4885 |
| US-20040077617-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | GRIN2A, GRIK1, GRIN2B | UGT2B7 1481/4885CYP1A2 907/4885EPHX1 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.